MX2023005395A - Formulaciones de peptidos y metodos de uso. - Google Patents
Formulaciones de peptidos y metodos de uso.Info
- Publication number
- MX2023005395A MX2023005395A MX2023005395A MX2023005395A MX2023005395A MX 2023005395 A MX2023005395 A MX 2023005395A MX 2023005395 A MX2023005395 A MX 2023005395A MX 2023005395 A MX2023005395 A MX 2023005395A MX 2023005395 A MX2023005395 A MX 2023005395A
- Authority
- MX
- Mexico
- Prior art keywords
- peptide
- methods
- formulations
- directed
- peptide formulations
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 241001479210 Human astrovirus Species 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063111367P | 2020-11-09 | 2020-11-09 | |
| PCT/US2021/057802 WO2022098682A1 (en) | 2020-11-09 | 2021-11-03 | Peptide formulations and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005395A true MX2023005395A (es) | 2023-05-19 |
Family
ID=81457409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005395A MX2023005395A (es) | 2020-11-09 | 2021-11-03 | Formulaciones de peptidos y metodos de uso. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230414506A1 (https=) |
| EP (1) | EP4240392A4 (https=) |
| JP (1) | JP2023549126A (https=) |
| KR (1) | KR20230106643A (https=) |
| CN (1) | CN116437938A (https=) |
| AU (1) | AU2021376124A1 (https=) |
| CA (1) | CA3194447A1 (https=) |
| IL (1) | IL302567A (https=) |
| MX (1) | MX2023005395A (https=) |
| WO (1) | WO2022098682A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022094372A1 (en) * | 2020-11-02 | 2022-05-05 | Realta Life Sciences, Inc. | Peptides and methods of use |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008013955A2 (en) * | 2006-07-27 | 2008-01-31 | Nektar Therapeutics | Sustained release formulations for pulmonary delivery |
| PT2432489T (pt) * | 2009-05-20 | 2016-12-07 | Biomarin Pharm Inc | Variantes do péptido natriurético de tipo c |
| SG11201510732VA (en) * | 2013-07-26 | 2016-01-28 | Sanofi Sa | Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation |
| ES2875498T3 (es) * | 2015-06-26 | 2021-11-10 | Realta Holdings Llc | Compuestos de péptidos sintéticos y procedimientos de uso |
| WO2017093810A2 (en) * | 2015-10-14 | 2017-06-08 | Pharcon Inc. | Composition for intraoral delivery of biologically active peptides and proteins |
| US12018054B2 (en) * | 2017-04-13 | 2024-06-25 | Valneva Austria Gmbh | Multivalent OspA polypeptides and methods and uses relating thereto |
| EP3740074B1 (en) * | 2018-01-09 | 2024-11-06 | ReAlta Holdings, LLC | Pic1 inhibition of myeloperoxidase oxidative activity in an animal model |
| US12441776B2 (en) * | 2018-11-30 | 2025-10-14 | Eirgen Pharma Ltd. | Oxyntomodulin peptide analog formulations |
| WO2020243220A1 (en) * | 2019-05-28 | 2020-12-03 | Realta Holdings, Llc | Pic1 peptide compositions and methods of use thereof for treatment of hypoxic ischemic encephalopathy |
-
2021
- 2021-11-03 CA CA3194447A patent/CA3194447A1/en active Pending
- 2021-11-03 EP EP21889935.9A patent/EP4240392A4/en active Pending
- 2021-11-03 IL IL302567A patent/IL302567A/en unknown
- 2021-11-03 KR KR1020237018965A patent/KR20230106643A/ko active Pending
- 2021-11-03 MX MX2023005395A patent/MX2023005395A/es unknown
- 2021-11-03 CN CN202180072873.1A patent/CN116437938A/zh active Pending
- 2021-11-03 AU AU2021376124A patent/AU2021376124A1/en active Pending
- 2021-11-03 US US18/035,846 patent/US20230414506A1/en active Pending
- 2021-11-03 WO PCT/US2021/057802 patent/WO2022098682A1/en not_active Ceased
- 2021-11-03 JP JP2023527357A patent/JP2023549126A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023549126A (ja) | 2023-11-22 |
| KR20230106643A (ko) | 2023-07-13 |
| IL302567A (en) | 2023-07-01 |
| US20230414506A1 (en) | 2023-12-28 |
| AU2021376124A1 (en) | 2023-06-29 |
| CA3194447A1 (en) | 2022-05-12 |
| WO2022098682A1 (en) | 2022-05-12 |
| EP4240392A1 (en) | 2023-09-13 |
| EP4240392A4 (en) | 2024-10-09 |
| CN116437938A (zh) | 2023-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2004246909B2 (en) | Antimicrobial and anticancer lipopeptides | |
| Reyes‐Díaz et al. | Immunomodulation by hydrolysates and peptides derived from milk proteins | |
| Werner et al. | Immunomodulating peptides | |
| MY199821A (en) | Modified lipidated relaxin b chain peptides and their therapeutic use | |
| WO2012012600A3 (en) | Peptide compounds for regulating the complement system | |
| MX2019006515A (es) | Composiciones que comprenden peptido wkdeagkplvk. | |
| RU2010111139A (ru) | Комбинированная терапия рака поджелудочной железы с использованием антигенного пептида и химиотерапевтического средства | |
| CN106232616A (zh) | 两亲性合成抗菌肽、其药物组合物及其用途 | |
| EP3501532A3 (en) | Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof | |
| Petrov et al. | Bone marrow immunoregulatory peptides (myelopeptides): isolation, structure, and functional activity | |
| NZ756128A (en) | Novel peptides and analogs for use in the treatment of oral mucositis | |
| JP2019104744A (ja) | コレステロール誘発性ミトコンドリア機能不全を治療するための芳香族カチオン性ペプチドの使用 | |
| MX9703642A (es) | Metodos para el tratamiento de esclerosis multiple utilizando analogos de peptido en la posicion 91 de la proteina basica de mielina humana. | |
| MX2021014497A (es) | Peptidos. | |
| US20250002854A1 (en) | Methods of generating populations of tumour-infiltrating t cells | |
| Garcia‐Redondo et al. | Vascular effects of egg white‐derived peptides in resistance arteries from rats. Structure–activity relationships | |
| MX2023005395A (es) | Formulaciones de peptidos y metodos de uso. | |
| MX2022008748A (es) | Administración oral de péptidos. | |
| CA2248630A1 (en) | Synthetic peptides and pseudopeptides having osteogenic activity and pharmaceutical compositions containing the same | |
| JOP20240271A1 (ar) | ببتيدات إظهار أنشطة منع فقدان العضلات وتعزيز الكتلة العضلية واستخداماتها | |
| EP3054969A2 (en) | Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions | |
| RU2009140209A (ru) | Средство для лечения связанных со стрессовыми условиями заболеваний и расстройств у человека и животных, а также способ лечения и/или профилактики с использованием этого средства | |
| RU2018145945A (ru) | Пептид для лечения остеоартрита, фармацевтическая композиция, лекарственное средство, единичная дозированная форма | |
| NZ723300A (en) | Compositions for the prevention and/or treatment of pathologies associated with alpha-glucosidase | |
| MX2023005134A (es) | Peptidos y metodos de uso. |